Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

ABSTRACT: Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

PROVIDER: PRJNA831648 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18909200_1.fastq.gz	Fastqsanger.gz
	SRR18909200_2.fastq.gz	Fastqsanger.gz
	SRR18909201_1.fastq.gz	Fastqsanger.gz
	SRR18909201_2.fastq.gz	Fastqsanger.gz
	SRR18909202_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 210

Similar Datasets

Development of potent and selective KDM5 covalent inhibitors

Project description:Development of potent and selective KDM5 covalent inhibitors

| PRJNA486160 | ENA

Development of potent and selective KDM5 covalent inhibitors

Project description:Histone lysine demethylase (KDMs) are involved in the dynamic regulation of gene expression by reversible regulation of the methylation levels on lysine residues in histone tails. Among the KDMs, the jumonji (JmjC)-domain-containing KDMs (KDM2-7) are Fe(II), 2- OG (α-ketoglutarate) and molecular oxygen-dependent enzymes that employ an oxygenase mechanism to demethylate specific methylation states at various histone sites. KDMs play a critical role in several biological processes such as cell differentiation, inflammation, cancer progression and resistance. Achieving selectivity over the different families of KDMs has been a major challenge. Here we report potent and selective KDM5 covalent inhibitors designed to target a cysteine residue only present in the KDM5 sub-family. In vitro assays show that compounds are selective for the KDM5 sub-family, showing potencies in the low nanomolar range, with higher affinity for KDM5A/B. The covalent binding to the targeted proteins was proved by MS. A kinetic approach was studied in order to describe the components of overall inhibitor potency (reversible binding and chemical reactivity), showing a time-dependent decrease of IC50 values for irreversible inhibition. Additional 2-OG competition assays show that compounds were non 2-OG competitive and target engagement and ChIPs-seq assays showed that the compounds inhibited the KDM5 members in cells in the low micromolar and they induce a global increase of the H3K4Me3 mark.

2018-12-10 | GSE118589 | GEO

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Project description:We report the expression result for the invivo and invitro cell lines treated with MRTX1133

2022-04-28 | GSE201412 | GEO

Discovery of a potent and selective covalent inhibitor and activity-based probe for UCHL1, with anti-fibrotic activity

Project description:Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme (DUB) that is very highly expressed in human brain. UCHL1 has been proposed as a potential therapeutic target in neurodegeneration, cancer, and liver and lung fibrosis, however bona fide molecular functions of UCHL1 are yet to be elucidated. Herein we characterize a potent and selective inhibitor and activity-based probe (IMP-1710) for UCHL1 based on a covalent inhibitor scaffold, and its application to identify and quantify target proteins in intact human cells. IMP-1710 stereoselectively labels the catalytic cysteine of UCHL1 at low nanomolar concentration, and we show that a previously claimed UCHL1 inhibitor (LDN-57444) fails to engage UCHL1 in cells. We further demonstrate that potent UCHL1 inhibitors selectively block pro-fibrotic responses in a cellular model of idiopathic pulmonary fibrosis (IPF), supporting a potential therapeutic role for UCHL1 inhibition.

2020-11-12 | PXD015825 | Pride

Amorfrutins are selective PPARγ agonists with potent antidiabetic properties

Project description:Amorfrutins are selective PPARγ agonists with potent antidiabetic properties

| PRJNA139093 | ENA

Development of a selective CDK7 covalent inhibitor reveals predominant cell cycle phenotype

Project description:Development of a selective CDK7 covalent inhibitor reveals predominant cell cycle phenotype

| PRJNA512643 | ENA

CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma (scRNA)

Project description:Mutations in KRAS are a dominant driver of pancreatic ductal adenocarcinoma (PDAC), with over 40% of PDAC patients presenting with KRASG12D mutations. The recent development of small molecule inhibitors targeting KRASG12D, has enabled effective targeting of mutant KRAS signaling and suppression of PDAC; however, the contribution of the tumor microenvironment (TME) to the therapeutic efficacy of KRASG12D inhibition and mechanism/s of resistance to KRASG12D suppression remain to be elucidated. Here, we employed spatial transcriptomics and CODEX-based spatial proteomics to evaluate cancer cell intrinsic and extrinsic responses to KRASG12D inhibition with MRTX1133. MRTX1133 treatment was associated with increased CD11c+ cells, T cells, and tumor-restraining fibroblasts within proximity to cancer cells, suggesting that antigen presentation and remodeling of the local microenvironment is associated with an effective response to KRASG12D inhibition. In the context of emergence of MRTX1133 therapy resistance, CDK8, a multiprotein mediator complex associated kinase, was identified as a mediator of resistance in part through induction of downstream CXCL2 chemokine secretion, inhibition of FAS expression, and remodeling of the TME to promote immune evasion. Targeting CDK8 in combination with aCTLA-4 immunotherapy overcomes resistance to small molecule mediated targeted KRASG12D inhibition with prolonged survival of mice with PDAC.

2025-12-02 | GSE269679 | GEO

CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreatic ductal adenocarcinoma (spatial)

2025-12-02 | GSE269680 | GEO

Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy

Project description:Covalent inhibitors of the oncoprotein KRAS have significant initial efficacy, but responses lack durability. Covalent inhibitor-modified oncoproteins are presented as MHC-restricted hapten-peptides (p*MHC) on the cancer cell surface, creating an opportunity to combine targeted therapy with immunotherapy to overcome drug resistance. Building on previous indirect evidence of KRASG12C-derived p*MHCs, we used immunopeptidomics to identify and directly quantify these synthetic neoantigens. Prompted by their low copy number, we developed AETX-R114, a T cell engaging bispecific antibody with picomolar affinity for MHC-restricted sotorasib-modified KRASG12C peptides presented by three alleles belonging to the HLA-A3 supertype. AETX-R114 dramatically increases the half-life and thereby the number of presented p*MHCs, enabling selective and potent killing of resistant cancer cells in vitro and in vivo. To broaden the therapeutic potential of creating and targeting synthetic neoantigens we developed AETX-R302, which recognizes divarasib-modified KRASG12C peptides presented on alleles from the HLA-A2 and HLA-A3 supertypes. Cryo-EM structure determination revealed the molecular basis for breaking HLA supertype restriction. Collectively, our study illustrates how engineered antibodies can transform synthetic neoantigens into actionable, specific-cancer immunotherapy targets.

2025-02-21 | MSV000097193 | MassIVE

Computational design of potent and selective BAK and BAX binders

Project description:Computational design of potent and selective BAK and BAX binders

| PRJNA1107244 | ENA